VA
ZNTL icon

Verdad Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Verdad Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Buy
+39,608
New +$158K 0.18% 158

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Verdad Advisers's ZNTL Position: Q2 2026 in Review

Verdad Advisers opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 39,608 shares worth $192K. The stake represents 0.18% of the portfolio and ranks #158 among its holdings.

114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Verdad Advisers held 39,608 shares of Zentalis Pharmaceuticals worth $192K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Verdad Advisers position in Q2 2026.
  • Zentalis Pharmaceuticals made up 0.18% of Verdad Advisers's portfolio in Q2 2026, its #158 holding.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.